SG10201913730RA - Cancer therapy - Google Patents
Cancer therapyInfo
- Publication number
- SG10201913730RA SG10201913730RA SG10201913730RA SG10201913730RA SG10201913730RA SG 10201913730R A SG10201913730R A SG 10201913730RA SG 10201913730R A SG10201913730R A SG 10201913730RA SG 10201913730R A SG10201913730R A SG 10201913730RA SG 10201913730R A SG10201913730R A SG 10201913730RA
- Authority
- SG
- Singapore
- Prior art keywords
- cancer therapy
- cancer
- therapy
- Prior art date
Links
- 238000011275 oncology therapy Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/664—Amides of phosphorus acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361811209P | 2013-04-12 | 2013-04-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201913730RA true SG10201913730RA (en) | 2020-03-30 |
Family
ID=50771615
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201509707QA SG11201509707QA (en) | 2013-04-12 | 2014-04-11 | Cancer therapy |
| SG10201913730RA SG10201913730RA (en) | 2013-04-12 | 2014-04-11 | Cancer therapy |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201509707QA SG11201509707QA (en) | 2013-04-12 | 2014-04-11 | Cancer therapy |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US10195219B2 (en) |
| EP (1) | EP2983673A2 (en) |
| JP (4) | JP2016516781A (en) |
| CN (3) | CN112023054A (en) |
| AU (3) | AU2014250795B2 (en) |
| BR (1) | BR112015024537B1 (en) |
| CA (1) | CA2909349C (en) |
| HK (1) | HK1220900A1 (en) |
| SG (2) | SG11201509707QA (en) |
| WO (1) | WO2014169221A2 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201509707QA (en) | 2013-04-12 | 2015-12-30 | Rebecca Lambert Bent | Cancer therapy |
| WO2016009256A1 (en) * | 2014-07-17 | 2016-01-21 | Probiotical S.P.A. | Compositions comprising melatonin and flavonoids for use in the treatment of tumours resistant to chemotherapy |
| EP3265071A1 (en) | 2015-03-05 | 2018-01-10 | Probiotical S.p.a. | Compositions for use in the treatment of tumors resistant to chemotherapy |
| EP3471713A1 (en) * | 2016-06-15 | 2019-04-24 | Deutsches Krebsforschungszentrum | Cancer treatment by simultaneous targeting energy metabolism and intracellular ph |
| SG10201609131YA (en) * | 2016-11-01 | 2018-06-28 | Xylonix Ip Holdings Pte Ltd | Zinc-pga compositions and methods for treating cancer |
| WO2019071007A1 (en) * | 2017-10-05 | 2019-04-11 | New York Genome Center, Inc. | Methods and compositions for targeting vascular mimicry |
| EP3784273A1 (en) * | 2018-04-25 | 2021-03-03 | Université catholique de Louvain | Combination of metformin and cyclophosphamide as an adjuvant in cancer immunotherapy |
| US20220111019A1 (en) * | 2018-09-19 | 2022-04-14 | Virginia Tech Intellectual Properties, Inc. | Brca1 modulating compounds, formulations thereof, and uses thereof |
| CN109674990A (en) * | 2019-01-30 | 2019-04-26 | 中国人民解放军西部战区总医院 | With the composition and preparation method thereof for adjusting EGFR effect |
| KR102347996B1 (en) * | 2020-03-02 | 2022-01-07 | 아주대학교산학협력단 | Pharmaceutical compositions for angiogenesis inhibition comprising metformin as an active ingredient |
| CN111419831B (en) * | 2020-04-08 | 2021-09-21 | 温州医科大学 | Application of metformin targeted COX6B2 in preparation of medicine for treating pancreatic cancer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4888346A (en) * | 1986-10-07 | 1989-12-19 | Bernard Bihari | Method for the treatment of persons infected with HTLV-III (AIDS) virus |
| ES2225822T3 (en) | 1992-05-19 | 2005-03-16 | Novogen Research Pty Ltd | USE OF ISOFLAVONAS PHYTO-STROGEN EXTRACTS FROM SOYBEAN OR TREBOL, ANALOGS OR METABOLITES OF THE SAME AND ITS USES. |
| WO2001078783A2 (en) | 2000-04-17 | 2001-10-25 | Hauser, Inc. | Compositions comprising natural agents for treatment of cancer |
| CN102958518A (en) * | 2009-05-15 | 2013-03-06 | 诺瓦提斯公司 | Combination of a phosphoinositide 3-kinase inhibitor and an antidiabetic compound for use in the treatment of proliferative diseases |
| MX2012002337A (en) * | 2009-08-25 | 2012-06-25 | Harvard College | Use of metformin in cancer treatment and prevention. |
| CA2820384A1 (en) | 2010-12-06 | 2012-06-14 | Cure Cancer Worldwide Corporation | Methods of metabolic targeting cancer cells using chemo- and immunotherapy for treating cancer |
| WO2012122295A2 (en) * | 2011-03-07 | 2012-09-13 | Ned Biosystems, Inc. | Treatment for pancreatic adenocarcinoma and other cancers of epithelial origin |
| SG11201509707QA (en) | 2013-04-12 | 2015-12-30 | Rebecca Lambert Bent | Cancer therapy |
-
2014
- 2014-04-11 SG SG11201509707QA patent/SG11201509707QA/en unknown
- 2014-04-11 US US14/351,766 patent/US10195219B2/en active Active
- 2014-04-11 BR BR112015024537-4A patent/BR112015024537B1/en active IP Right Grant
- 2014-04-11 WO PCT/US2014/033820 patent/WO2014169221A2/en active Application Filing
- 2014-04-11 CA CA2909349A patent/CA2909349C/en active Active
- 2014-04-11 AU AU2014250795A patent/AU2014250795B2/en active Active
- 2014-04-11 CN CN202010928624.5A patent/CN112023054A/en active Pending
- 2014-04-11 CN CN201480020831.3A patent/CN105120876A/en active Pending
- 2014-04-11 EP EP14725855.2A patent/EP2983673A2/en not_active Ceased
- 2014-04-11 JP JP2016507686A patent/JP2016516781A/en not_active Withdrawn
- 2014-04-11 CN CN202010927983.9A patent/CN112022853A/en active Pending
- 2014-04-11 SG SG10201913730RA patent/SG10201913730RA/en unknown
-
2016
- 2016-07-27 HK HK16108998.7A patent/HK1220900A1/en unknown
-
2018
- 2018-05-11 JP JP2018092024A patent/JP6757360B2/en active Active
- 2018-11-02 US US16/179,722 patent/US11083740B2/en active Active
-
2019
- 2019-09-09 JP JP2019163624A patent/JP6870046B2/en active Active
- 2019-09-24 AU AU2019236645A patent/AU2019236645B9/en active Active
-
2020
- 2020-10-07 JP JP2020169866A patent/JP2021001234A/en active Pending
-
2021
- 2021-07-02 US US17/366,830 patent/US20220168324A1/en active Pending
-
2022
- 2022-04-28 AU AU2022202814A patent/AU2022202814A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112015024537B1 (en) | 2022-09-06 |
| JP6757360B2 (en) | 2020-09-16 |
| AU2019236645A1 (en) | 2019-10-17 |
| HK1220900A1 (en) | 2017-05-19 |
| JP2019203034A (en) | 2019-11-28 |
| US20160030454A1 (en) | 2016-02-04 |
| AU2019236645B2 (en) | 2022-02-03 |
| JP2016516781A (en) | 2016-06-09 |
| CA2909349A1 (en) | 2014-10-16 |
| CA2909349C (en) | 2023-01-03 |
| JP6870046B2 (en) | 2021-05-12 |
| JP2021001234A (en) | 2021-01-07 |
| AU2022202814A1 (en) | 2022-05-19 |
| BR112015024537A8 (en) | 2019-12-10 |
| US20220168324A1 (en) | 2022-06-02 |
| CN112023054A (en) | 2020-12-04 |
| EP2983673A2 (en) | 2016-02-17 |
| JP2018119013A (en) | 2018-08-02 |
| BR112015024537A2 (en) | 2017-07-18 |
| SG11201509707QA (en) | 2015-12-30 |
| WO2014169221A2 (en) | 2014-10-16 |
| US10195219B2 (en) | 2019-02-05 |
| WO2014169221A3 (en) | 2015-01-15 |
| AU2019236645B9 (en) | 2022-06-02 |
| AU2014250795B2 (en) | 2019-07-18 |
| AU2014250795A1 (en) | 2015-09-03 |
| US20190175626A1 (en) | 2019-06-13 |
| CN105120876A (en) | 2015-12-02 |
| US11083740B2 (en) | 2021-08-10 |
| CN112022853A (en) | 2020-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL245731A0 (en) | Combination therapy for treating cancer | |
| GB201322725D0 (en) | Cancer therapy | |
| EP2968343A4 (en) | Combination therapy for treating cancer | |
| HK1220900A1 (en) | Cancer therapy | |
| SG10201801965RA (en) | Treatment of cancer with dihydropyrazino-pyrazines | |
| SG11201507847UA (en) | Cancer therapy | |
| IL242017B (en) | Treatment of cancer with dihydropyrazino-pyrazines | |
| EP3007756A4 (en) | Catheter-assisted tumor treatment | |
| GB201308440D0 (en) | Therapeutic | |
| ZA201507755B (en) | Tumor-selective combination therapy | |
| EP3044593A4 (en) | Cancer therapy | |
| GB201310755D0 (en) | Therapy | |
| HK1215195A1 (en) | Caix stratification based cancer treatment caix | |
| EP2961412A4 (en) | Cancer therapy | |
| HK1223547A1 (en) | Methods for the treatment of cancer | |
| GB201403083D0 (en) | Treatment of cancer | |
| GB201318668D0 (en) | Sonosensitive therapeutic | |
| HK1232118A1 (en) | Treatment of cancer | |
| GB201307269D0 (en) | Combination Therapy | |
| GB201308039D0 (en) | Photodynamic therapy | |
| GB201518731D0 (en) | Tumour Therapy | |
| PL3016948T3 (en) | 2-acylaminothiazoles for the treatment of cancer | |
| EP3013332A4 (en) | Cancer treatment | |
| GB201317213D0 (en) | Cancer Therapy | |
| GB201308365D0 (en) | Tumour therapy |